Careteq Limited Secures AU$2.2M Capital Raise to Drive Strategic Growth Initiatives
Source: Kapitales Research
Highlights:
Careteq Limited (ASX: CTQ) has raised AU$2.2 million through a two-tranche placement, issuing approximately 440 million shares at AU$0.005 per share.
The capital will be directed towards project acquisitions, reducing debt, and enhancing working capital to support the company’s ongoing initiatives.
At the time of writing, the stock’s CMP was AU$0.008, up about 14%, as investors reacted positively to the capital raising announcement.
Careteq Limited Successfully Completes Capital Raise
Careteq Limited (ASX: CTQ) has successfully completed a AU$2.2 million capital raise through the placement of 440 million new shares at a price of AU$0.005 each. This capital raising was well received, with commitments from both existing and new investors, which will help reinforce Careteq’s financial position.
At the time of writing, the stock was trading at AU$0.008, representing a 14% increase, as market participants reacted positively to the funding and the company’s plans for utilizing the capital.
Placement Structure and Use of Funds
The placement consists of two tranches, with the first tranche raising AU$193,000 through the issuance of around 38.6 million shares, which will be issued under Careteq’s existing placement capacity. The second tranche, which consists of 401.3 million shares, will be issued pending shareholder approval at an Extraordinary General Meeting (EGM) set for April 2026.
The funds raised will be allocated towards advancing strategic goals, including funding project acquisitions, reducing outstanding debt, and supporting ongoing operational requirements.
Investing in Healthcare Technology Growth
Careteq, which focuses on healthtech innovation, is committed to improving healthcare outcomes through its Embedded Health Solutions (EHS) and HMR Referrals platforms. With the additional capital, Careteq plans to expand these platforms and explore new growth opportunities within the healthcare technology sector.
With a solid financial foundation in place, Careteq is positioned to further its efforts in delivering cutting-edge solutions in medication management and solidifying its leadership in the healthtech industry.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Careteq Limited Secures AU$2.2M Capital Raise to Drive Strategic Growth Initiatives
Highlights:
Careteq Limited Successfully Completes Capital Raise
Careteq Limited (ASX: CTQ) has successfully completed a AU$2.2 million capital raise through the placement of 440 million new shares at a price of AU$0.005 each. This capital raising was well received, with commitments from both existing and new investors, which will help reinforce Careteq’s financial position.
At the time of writing, the stock was trading at AU$0.008, representing a 14% increase, as market participants reacted positively to the funding and the company’s plans for utilizing the capital.
Placement Structure and Use of Funds
The placement consists of two tranches, with the first tranche raising AU$193,000 through the issuance of around 38.6 million shares, which will be issued under Careteq’s existing placement capacity. The second tranche, which consists of 401.3 million shares, will be issued pending shareholder approval at an Extraordinary General Meeting (EGM) set for April 2026.
The funds raised will be allocated towards advancing strategic goals, including funding project acquisitions, reducing outstanding debt, and supporting ongoing operational requirements.
Investing in Healthcare Technology Growth
Careteq, which focuses on healthtech innovation, is committed to improving healthcare outcomes through its Embedded Health Solutions (EHS) and HMR Referrals platforms. With the additional capital, Careteq plans to expand these platforms and explore new growth opportunities within the healthcare technology sector.
With a solid financial foundation in place, Careteq is positioned to further its efforts in delivering cutting-edge solutions in medication management and solidifying its leadership in the healthtech industry.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au